Literature DB >> 28049548

Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia.

Vasthie Prudent1, William S Breitbart1.   

Abstract

Chimeric antigen receptor T cells are used in the treatment of B-cell leukemias. Common chimeric antigen receptor T-cell toxicities can range from mild flu-like symptoms, such as fever and myalgia, to a more striking neuropsychiatric toxicity that can present as discrete neurological symptoms and delirium. We report here two cases of chimeric antigen receptor T-cell neuropsychiatric toxicity, one who presented as a mild delirium and aphasia that resolved without intervention, and one who presented with delirium, seizures, and respiratory insufficiency requiring intensive treatment. The current literature on the treatment and proposed mechanisms of this clinically challenging chimeric antigen receptor T-cell complication is also presented.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Chimeric antigen receptor; Cytokine release syndrome; Neurotoxicity

Mesh:

Substances:

Year:  2017        PMID: 28049548      PMCID: PMC5496800          DOI: 10.1017/S147895151600095X

Source DB:  PubMed          Journal:  Palliat Support Care        ISSN: 1478-9515


  16 in total

1.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Authors:  Daniel W Lee; James N Kochenderfer; Maryalice Stetler-Stevenson; Yongzhi K Cui; Cindy Delbrook; Steven A Feldman; Terry J Fry; Rimas Orentas; Marianna Sabatino; Nirali N Shah; Seth M Steinberg; Dave Stroncek; Nick Tschernia; Constance Yuan; Hua Zhang; Ling Zhang; Steven A Rosenberg; Alan S Wayne; Crystal L Mackall
Journal:  Lancet       Date:  2014-10-13       Impact factor: 79.321

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Authors:  David S Ritchie; Paul J Neeson; Amit Khot; Stefan Peinert; Tsin Tai; Kellie Tainton; Karen Chen; Mandy Shin; Dominic M Wall; Dirk Hönemann; Peter Gambell; David A Westerman; Javier Haurat; Jennifer A Westwood; Andrew M Scott; Lucy Kravets; Michael Dickinson; Joseph A Trapani; Mark J Smyth; Phillip K Darcy; Michael H Kershaw; H Miles Prince
Journal:  Mol Ther       Date:  2013-07-08       Impact factor: 11.454

Review 4.  CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).

Authors:  Sarah K Tasian; Rebecca A Gardner
Journal:  Ther Adv Hematol       Date:  2015-10

5.  Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Authors:  Esther Drent; Richard W J Groen; Willy A Noort; Maria Themeli; Jeroen J Lammerts van Bueren; Paul W H I Parren; Jürgen Kuball; Zsolt Sebestyen; Huipin Yuan; Joost de Bruijn; Niels W C J van de Donk; Anton C M Martens; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

6.  IL-6 regulation of synaptic function in the CNS.

Authors:  Donna L Gruol
Journal:  Neuropharmacology       Date:  2014-11-22       Impact factor: 5.250

7.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

8.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Authors:  David L Porter; Wei-Ting Hwang; Noelle V Frey; Simon F Lacey; Pamela A Shaw; Alison W Loren; Adam Bagg; Katherine T Marcucci; Angela Shen; Vanessa Gonzalez; David Ambrose; Stephan A Grupp; Anne Chew; Zhaohui Zheng; Michael C Milone; Bruce L Levine; Jan J Melenhorst; Carl H June
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

9.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

10.  Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer.

Authors:  Yu Cao; David T Rodgers; Juanjuan Du; Insha Ahmad; Eric N Hampton; Jennifer S Y Ma; Magdalena Mazagova; Sei-Hyun Choi; Hwa Young Yun; Han Xiao; Pengyu Yang; Xiaozhou Luo; Reyna K V Lim; Holly M Pugh; Feng Wang; Stephanie A Kazane; Timothy M Wright; Chan Hyuk Kim; Peter G Schultz; Travis S Young
Journal:  Angew Chem Int Ed Engl       Date:  2016-05-04       Impact factor: 15.336

View more
  6 in total

Review 1.  CAR T Cell Therapy for Hematological Malignancies.

Authors:  Xin Yang; Gao-Xiang Wang; Jian-Feng Zhou
Journal:  Curr Med Sci       Date:  2019-12-16

Review 2.  Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.

Authors:  Juliane Gust; Agne Taraseviciute; Cameron J Turtle
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

Review 3.  Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.

Authors:  Zhenguang Wang; Weidong Han
Journal:  Biomark Res       Date:  2018-01-22

Review 4.  CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.

Authors:  Qingyang Zhang; Jieming Ping; Zirui Huang; Xiaoli Zhang; Jingyi Zhou; Gangyang Wang; Shaoyang Liu; Jianjun Ma
Journal:  J Immunol Res       Date:  2020-01-17       Impact factor: 4.818

Review 5.  MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)-Current Treatment Options. Is There a Role for CAR-T Cell Therapy?

Authors:  Oliver Britten; Denise Ragusa; Sabrina Tosi; Yasser Mostafa Kamel
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

Review 6.  Considerations for setting occupational exposure limits for novel pharmaceutical modalities.

Authors:  Jessica C Graham; Jedd Hillegass; Gene Schulze
Journal:  Regul Toxicol Pharmacol       Date:  2020-11-02       Impact factor: 3.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.